• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Society for Clinical Research Sites adds Covance as Global Impact Partner

Society for Clinical Research Sites adds Covance as Global Impact Partner

July 6, 2015
CenterWatch Staff

The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, has announced a two-year partnership with Laboratory Corporation of America Holdings (LabCorp). Covance Drug Development will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.

"Covance's commitment to partner with SCRS as a GIP demonstrates that establishing positive site relationships is a high priority for them," said Christine Pierre, SCRS president. "SCRS' GIPs are focused on acknowledging the realities that today's sites face, and actively addressing their challenges. SCRS is proud to welcome Covance as our newest Global Impact Partner."

"Covance is committed to serving the clinical research community as a strong scientific partner in order to speed the development of innovative medicines that meet today's global healthcare needs," said Jill Johnston, global vice president, site activation, informatics and optimization, Covance. "Our work with SCRS will help us better understand the needs of our clinical research partners and ultimately improve service to our pharmaceutical and biotechnology clients."

As a GIP, Covance will participate on the SCRS Global Impact Board at an executive level, and work in tandem with SCRS' Leadership Council in the development and execution of strategic initiatives for SCRS.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing